PRESS




DECEMBER 13, 2012
CardioComm Solutions, Inc. receives CE Mark approval for HeartCheck™ Handheld ECG Device sale in europe
TORONTO, ONTARIO - CardioComm Solutions, Inc. is pleased to announce today they have received CE clearance for over the counter (OTC) and prescription-­‐use sales and marketing of their HeartCheck™ PEN ECG and HeartCheck™ ECG Monitor devices.


OCTOBER 22, 2012
Heart and Stroke Foundation and CardioComm Solutions Release first HeartCheck™ ECG Screening Results for Atrial Fibrillation Detection in Stroke Prevention Program
TORONTO, ONTARIO - CardioComm Solutions, Inc. announced today the positive results on the diagnostic accuracy of an arrhythmia screening project with the Heart and Stroke Foundation of Canada and St. Michael's Hospital (Toronto), using the HeartCheck™ ECG Monitor, and the Company's SMART Monitoring solution.


OCTOBER 3, 2012
CardioComm Solutions Welcomes 2012 North American Cardiac Rhythm Monitoring Enabling Technology Awarded by Frost & Sullivan
TORONTO, ONTARIO - CardioComm Solutions, Inc. was awarded the 2012 North American Cardiac Rhythm Monitoring Enabling Technology Award by Frost & Sullivan as announced first by Frost & Sullivan in a September 25, 2012, press release.


SEPTEMBER 11, 2012
CardioComm Solutions Files for FDA for Clearance of GUAVA™ II, a New ECG Viewer with ECG Algorithm Technologies.
TORONTO, ONTARIO - CardioComm Solutions, Inc. has submitted an application with the U.S. Food and Drug Administration ("FDA") for clearance of its GUAVA™ II ECG viewer technology.


SEPTEMBER 6, 2012
Health Canada Approves the HeartCheck™ ECG PEN for Over-The­-Counter Sales: CardioComm Solutions, Inc. Will Launch the HeartCheck™ Brand in Canada and the United Sates into both Consumer and Medical Markets.
TORONTO, ONTARIO - CardioComm Solutions, Inc. has received clearance from Health Canada for the sales and marketing of their HeartCheck™ ECG PEN to both consumers and patients under physician prescription.


AUGUST 29, 2012
CardioComm Solutions Receives Health Canada Approval to Market the HeartCheck™ ECG Monitor as a Prescription Product.
TORONTO, ONTARIO - CardioComm Solutions, Inc. has received clearance from Health Canada for the sales and marketing of their Class II medical device for prescription based, hand-held ECG monitoring under the HeartCheck™ brand.


AUGUST 17, 2012
CardioComm Solutions Partners with the Heart and Stroke Foundation of Canada on Atrial Fibrillation Detection and Stoke Prevention
TORONTO, ONTARIO - CardioComm Solutions, Inc. and its flagship FDA cleared HeartCheckTM ECG monitor will be highly visible at today's launch of the Heart and Stroke Foundation of Canada's (Heart and Stroke) electrocardiogram ("ECG") based screening program for the detection of atrial fibrillation (AF) and other arrhythmias, being run at the Canadian National Exhibition in Toronto.


JUNE 28, 2012
CardioComm Solutions' Technology Selected for Public ECG based Atrial Fibrillation Screening in 10,000 Canadians for the Heart and Stroke Foundation.
TORONTO, ONTARIO - CardioComm Solutions, Inc. has been contracted by the Heart and Stroke Foundation ("HSF") as the preferred provider to run a electrocardiogram ("ECG") screening program in Canada for the detection of cardiac arrhythmias with specific emphasis on the most difficult to find arrhythmia, Atrial Fibrillation ("AF").


MAY 23, 2012
CardioComm Solutions Receives FDA Clearance for Prescription Use of the HeartCheck™ ECG PEN.
TORONTO, ONTARIO - CardioComm Solutions, Inc. announced it has received clearance from the Food and Drug Administration (FDA) for "prescription-­‐use" sales and marketing of their hand-­‐held heart rhythm monitor known as the HeartCheck™ ECG PEN.


MARCH 30, 2012
CardioComm Solutions HeartCheck™ ECG Monitor Used for Atrial Fibrillation Screening in Collaboration with the Heart and Stroke Foundation of Canada
TORONTO, ONTARIO - CardioComm Solutions, Inc. has been requested by the Heart and Stroke Foundation of Canada to support an Atrial Fibrillation ("AF") screening initiative using electrocardiogram ("ECG") readings instead of pulse count. The screening will be conducted during the annual heart symposium of the Foundation's Chinese Canadian Council.


FEBRUARY 23, 2012
CardioComm Solutions Launches the HeartCheck™ Website: Begins HeartCheck™ Pen online order reservations
TORONTO, ONTARIO - CardioComm Solutions, Inc. announced the launch of its new HeartCheck™ website (www.theheartcheck.com). This initiative kicks off the company's 2012 Marketing Communications Campaign in support of the their entry into the consumer, over-the-counter (OTC) and prescribed Health Care Market and follows the recent Food and Drug Administration (FDA) OTC clearance of the HeartCheck™ Pen Hand Held ECG device.


FEBRUARY 14, 2012
CardioComm Solutions Executes an ECG Monitoring Service Agreement with Meditel of Italy and Places Soft-Launch HeartCheck™ PEN Order
TORONTO, ONTARIO - CardioComm Solutions, Inc. and Italian-based Meditel S.R.L. (Milan, Italy; "Meditel") have executed a four year Software License, Usage and Service Agreement. The agreement will allow Meditel the continued use of CardioComm Solutions' proprietary, internetbased ECG service software known as GlobalCardioTM.


JANUARY 24, 2012
CardioComm Solutions, Inc. Passes Canadian Medical Devices Conformity Assessment System ISO 13485:2003 Audit
TORONTO, ONTARIO - CardioComm Solutions, Inc. received confirmation from the Canadian Medical Devices Conformity Assessment System (CMDCAS) that it had cleared an ISO audit performed by DQS Medizinprodukte GmbH.


JANUARY 19, 2012
CardioComm Solutions, Inc. Receives FDA Clearance to Market First Over the-Counter Heart Monitoring Solution
TORONTO, ONTARIO - CardioComm Solutions, Inc. received clearance from the Food and Drug Administration (FDA) for over-the-counter (OTC) sales and marketing of their consumer-based, hand-held heart rhythm monitor known as the HeartCheck™ Pen Handheld ECG.